Clene Inc. Files 8-K: Other Events & Financials

TL;DR

Clene Inc. filed an 8-K on 7/11/24 for other events and financials. Stay tuned.

AI Summary

Clene Inc. filed an 8-K on July 11, 2024, reporting other events and financial statements. The company, previously known as Chelsea Worldwide Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located in Salt Lake City, Utah.

Why It Matters

This filing provides an update on Clene Inc.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.

Key Numbers

• 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)

Key Players & Entities

• Clene Inc. (company) — Registrant
• Chelsea Worldwide Inc. (company) — Former company name
• July 11, 2024 (date) — Date of earliest event reported
• Salt Lake City, Utah (location) — Principal executive offices location
• 001-39834 (other) — SEC File Number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value CLNN The Nasdaq Capital M
• $11.50 — e-half of one share of Common Stock for $11.50 per share CLNNW The Nasdaq Capital

Filing Documents

• clnn20240711_8k.htm (8-K) — 28KB
• ex_697239.htm (EX-99.1) — 12KB
• 0001437749-24-022529.txt ( ) — 190KB
• clnn-20240711.xsd (EX-101.SCH) — 4KB
• clnn-20240711_def.xml (EX-101.DEF) — 13KB
• clnn-20240711_lab.xml (EX-101.LAB) — 17KB
• clnn-20240711_pre.xml (EX-101.PRE) — 13KB
• clnn20240711_8k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On July 11, 2024, Clene Inc. (the "Company") issued a press release announcing plans to submit a briefing book to the U.S. Food and Drug Administration ("FDA") in connection with a granted Type C interaction to obtain FDA feedback on the potential pathway to accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis ("ALS"). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press release, dated July 11, 2024, announcing plans to submit briefing book to the FDA in connection with granted Type C interaction to obtain FDA feedback on potential pathway to accelerated approval for CNM-Au8 in ALS. 104 Cover Page Interactive Data File (formatted as Inline XBRL). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CLENE INC. Date: July 11, 2024 By: /s/ Robert Etherington Robert Etherington President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR